Loading...
Wave Life Sciences Q1 2025 Earnings Report
Wave Life Sciences reported its first quarter 2025 financial results with a decrease in revenue and an increase in net loss compared to the prior year.
Key Takeaways
Wave Life Sciences reported a net loss of $46.878 million for the first quarter of 2025, compared to a net loss of $31.558 million in the prior year quarter. Revenue decreased to $9.175 million from $12.538 million in the same period last year. The company ended the quarter with $243.075 million in cash and cash equivalents, with a runway expected into 2027.
Dosing completed in the first two cohorts of INLIGHT trial for WVE-007 in obesity, with clinical data expected in 2H 2025.
Dosing underway in RestorAATion-2 clinical trial for WVE-006, with data from complete 200 mg multidose and single dose cohorts expected in 3Q 2025.
Positive data delivered from FORWARD-53 clinical trial for WVE-N531 in DMD, with NDA submission planned for 2026.
IND submission expected 2H 2025 for potentially registrational WVE-003 Phase 2/3 study in HD.
Wave Life Sciences
Wave Life Sciences
Forward Guidance
Wave Life Sciences expects to deliver multiple clinical datasets in 2025, including clinical data from INLIGHT in 2H 2025, and data from RestorAATion-2 in 3Q 2025 and Fall 2025. The company also plans for NDA submission for WVE-N531 in 2026 and IND submission for WVE-003 in 2H 2025.
Positive Outlook
- Clinical data from INLIGHT trial (WVE-007) in obesity expected in 2H 2025.
- Data from complete 200 mg multidose and single dose cohorts of RestorAATion-2 (WVE-006) expected in 3Q 2025.
- Data from complete 400 mg single dose cohort of RestorAATion-2 (WVE-006) expected in Fall 2025.
- NDA submission for accelerated approval of WVE-N531 in DMD planned for 2026.
- IND submission for potentially registrational WVE-003 Phase 2/3 study in HD expected in 2H 2025.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.